According to Dr. Erba in the Venetoclax Based Chemotherapy transcript, he mentioned the response analysis and DOR and survival based in mutational analysis. Some pts had high responses and long duration compared to other pts with low responses and survival less than 6 months

Based on a small randomized Phase 2 study at MD Anderson there was a statistically significant difference in OS between decitabine 10-day versus decitibine 5-day in TP53 mutated AML patients

The Oral Azacitidine maintenace trial in AML

A Chromosome 5 or 7 on a FISH test is a strong clue for this mutation

For patients with core binding abnormalities, what agent can be added to standard IC therapy

According to Dr. Daver, this is becoming the largest referral population failure relapse, leaving few options and the need for new therapies

T/F Question: FLT-3 TKD is a point mutation affecting approximately 17% of AML patients

The primary endpoint in the Oral Azacitidine study

A test for mutations, such as FLT3 or IDH, with a turn-around time of 2 or 3 days

T/F Question: NGS is an acceptable method to determine MRD in patients with AML

Published large Phase 1 Studies have led to the approval of Ven plus 2 backbone therapies

Shawn Gilbertson recently wore a tie on our company call. DO you remember the color

The OS hazard ratio for oral Azacitidine versus placebo in the Quazar study

Adding Mylotarg to an induction treatment strategy is appropriate when the FISH test shows what

These two laboratory procedures are used to determine MRD in AML

In the transcript, Venetoclax Regimens for Chemotherapy, they mentioned a relapse co-hort from the FLAG-IDA front-line trial. There were 20 pts. The CR, Cri was 75% and half went to transplant. Unfortunately, this was not so great according to the data analysis

Anthony Porcaro's choice of Vodka

The dosing schedule for the Oral Azacitidine in the Quazar study

A test that provides an abundance of information but may take up to 2 weeks to obtain

T/F Question:MRD-positive patients have better outcomes post-transplant

Dr. Komrokji on the topic of managing toxicities, said that dosing Ven could be tricky and you had to find the "sweet spot". He will adjust the starting dose of 400 mg for pts on this type of therapy.

If a patient is deemed fit enough to withstand or not die from intensive induction chemotherapy in the modern era, then the physician should commit to that treatment

T/F Question: The 3 most over-rated things in life are; 1) Out of town romance 2 ) Leftovers 3)Data from MD Anderson

A test with the quickest turnaround time of 1 or 2 days is called this

The HOBON analysis indicated which 3 mutations do not impact long-term prognosisWhat is ASXL-1, TET2 ,DNAM3A?